Amyloid PET imaging in lewy body disorders

American Journal of Geriatric Psychiatry

Volumn 23, Issue 1, 2015, Pages 23-37

  Donaghy, Paul ^a   Thomas, Alan J ^a   O'Brien, John T ^b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Amyloid; dementia; imaging; Lewy bodies; Parkinson disease; positron emission tomography

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; AMYLOID BRAIN IMAGING; ARTICLE; AUTOPSY; COGNITIVE DEFECT; DIAGNOSIS RELATED GROUP; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; IMAGE ANALYSIS; LEWY BODY; LIGAND BINDING; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; ONSET AGE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER; REM SLEEP; SLEEP DISORDER; TREATMENT RESPONSE; BRAIN CORTEX; DEMENTIA; METABOLISM; PROCEDURES;

AMYLOID BETA-PEPTIDES; CEREBRAL CORTEX; DEMENTIA; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 84928044579     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.03.001     Document Type: Article

References (74)

1. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clin ical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996; 47:1113-1124
2. Stevens T, Livingston G, Kitchen G, et al: Islington study of dementia subtypes in the community. Br J Psychiatry 2002; 180:270-276
3. Emre M, Aarsland D, Brown R, et al: Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22:1689-1707; quiz 1837
4. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 65:1863-1872
5. McKeith I: Commentary: DLB and PDD: The same or different? Is there a debate? Int Psychogeriatr 2009; 21:220-224
6. Kovari E, Horvath J, Bouras C: Neuropathology of Lewy body disorders. Brain Res Bull 2009; 80:203-210
7. Merdes AR, Hansen LA, Jeste DV, et al: Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586-1590
8. Weisman D, Cho M, Taylor C, et al: In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology 2007; 69:356-359
9. Del Ser T, Hachinski V, Merskey H, et al: Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: Effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord 2001; 1 5:31-44
10. Nelson PT, Kryscio RJ, Jicha GA, et al: Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology 2009; 73:1127-1133
11. Ballard C, Ziabreva I, Perry R, et al: Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67:1931-1934
12. Fujishiro H, Iseki E, Higashi S, et al: Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010; 486:19-23
13. Selikhova M, Williams DR, Kempster PA, et al: A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009; 132: 2947-2957
14. Aarsland D, Ballard CG, Halliday G: Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17:137-145
15. Jellinger KA, Seppi K, Wenning GK: Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol 2003; 106:188-189; author reply 190
16. Pletnikova O, West N, Lee MK, et al: Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26:1183-1192
17. Rowe CC Villemagne VL Brain amyloid imaging J Nucl Med 2011 52 1733-1740
18. Sojkova J, Driscoll I, Iacono D, et al: In vivo fibrillar beta-amyloid detected using [11C]PiB po sitron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 68:232-240
19. Clark CM, Schneider JA, Bedell BJ, et al: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275-283
20. Ikonomovic MD, Klunk WE, Abrahamson EE, et al: Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645
21. Quigley H, Colloby SJ, O'Brien JT: PET imaging of brain amyloid in dementia: A review. Int J Geriatr Psychiatry 2011; 26:991-999
22. Rosenberg PB, Wong DF, Edell SL, et al: Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry 2013; 21: 272-278
23. Edison P, Rowe CC, Rinne JO, et al: Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C] PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79:1331-133 8
24. Gomperts SN, Rentz DM, Moran E, et al: Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71:903-910
25. Gomperts SN, Locascio JJ, Marquie M, et al: Brain amyloid and cognition in Lewy body diseases. Mov Disord 2012; 27:965-973
26. Kantarci K, Lowe VJ, Boeve BF, et al: Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33:2091-2105
27. Foster ER, Campbell MC, Burack MA, et al: Amyloid imaging of Lewy body-associated disorders. Mov Disord 2010; 25:2516-2523
28. Villemagne VL, Ong K, Mulligan RS, et al: Amyloid Imaging with F-18-Florbetaben in Alzheimer Disease and Other Dementias. J Nucl Med 2011; 52:1210-1217
29. Claassen DO, Lowe VJ, Peller P J, et al: Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy. Parkinsonism Relat Disord 2011; 17:160-165
30. Rowe CC, Ng S, Ackermann U, et al: Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68:1718-1725
31. Maetzler W, Reimold M, Liepelt I, et al: [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008; 39:1027-1033
32. Petrou M, Bohnen NI, Muller ML, et al: Abeta-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology 2012; 79:1161-1167
33. Maetzler W, Liepelt I, Reimold M, et al: Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34:107-112
34. Shimada H, Shinotoh H, Hirano S, et al: Beta-amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28:169-175
35. Jokinen P, Scheinin N, Aalto S, et al: [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010; 16:666-670
36. Johansson A, Savitcheva I, Forsberg A, et al: [(11)C]-PIB imaging in patients with Parkinson's disease: Preliminary results. Parkinsonism Relat Disord 2008; 14:345-347
37. Gomperts SN, Locascio JJ, Rentz D, et al: Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013; 80:85-91
38. Graff-Radford J Boeve BF Pedraza O et al Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies Brain 2012 135 2470-2477
39. Fleisher AS, Chen K, Liu X, et al: Apolip oprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013; 34: 1-12
40. Drzezga A, Grimmer T, Henriksen G, et al: Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 2009; 72:1487-1494
41. Sinha N, Firbank M, O'Brien JT: Biomarkers in dementia with Lewy bodies: A review. Int J Geriatr Psychiatry 2012; 27:443-453
42. Burke JF, Albin RL, Koeppe RA, et al: Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011; 134:1647-1657
43. Ossenkoppele R, Prins ND, Pijnenburg YA, et al: Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimers Dement 2013; 9:414-421
44. Bacskai BJ, Frosch MP, Freeman SH, et al: Molecular imaging with Pittsburgh Compound B confirmed at autopsy: A case report. Arch Neurol 2007; 64:431-434
45. Burack MA, Hartlein J, Flo res HP, et al: In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74:77-84
46. Kantarci K, Yang C, Schneider JA, et al: Ante mortem amyloid imaging and beta-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012; 33:878-885
47. Ikonomovic MD, Abrahamson EE, Price JC, et al: Early AD pathology in a C-11 PiB-negative case: A PiB-amy loid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012; 123:433-447
48. Harding AJ, Halliday GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001; 102:355-363
49. Jellinger KA, Attems J: Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease. Acta Neuropathol 2008; 115:427-436
50. Compta Y, P arkkinen L, O'Sullivan SS, et al: Lewy-and Alzheimertype pathologies in Parkinson's disease dementia: Which is more important? Brain 2011; 134:1493-1505
51. Irwin DJ, White MT, Toledo JB, et al: Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012; 72:587-598
52. Mirra SS, Heyman A, McKeel D, et al: The Cons ortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41:479-486
53. Kempster PA, Williams DR, Selikhova M, et al: Patterns of levodopa response in Parkinson's disease: A clinico-pathological study. Brain 2007; 130:2123-2128
54. Jellinger KA, Sepp i K, Wenning GK, et al: Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm 2002; 109:329-339
55. Aarsland D, Perry R, Brown A, et al: Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. Ann Neurol 2005; 58:773-776
56. Lashley T, Holton JL, Gray E, et al: Cortical alpha-synuclein load is associated wi th amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008; 115:417-425
57. Ballard CG, Jacoby R, Del Ser T, et al: Neuropathological substrates of psychiatric symp toms in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J Psychiatry 2004; 161:843-849
58. Masliah E, Rockenstein E, Veinbergs I, et al: Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci USA 2001; 98: 12245-12250
59. Clinton LK, Blurton-Jones M, Myczek K, et al: Synergistic Interactions between Abeta, tau, and alpha-synuclein: Acceleration of neuropathology and cognitive decline. J Neurosci 2010; 30: 7281-7289
60. Serby M Brickman AM Haroutunian V et al Cognitive burden and excess Lewy-body pathology in the Lewy-body variant of Alzheimer disease. Am J Geriatr Psychiatry 2003 11 371-374
61. Kraybill ML, Larson EB, Tsuang DW, et al: Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64:2069-2073
62. Mattila PM, Rinne JO, Helenius H, et al: Alpha-synuclein-immunor eactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000; 100: 285-290
63. Braak H, Rub U, Jansen Steur EN, et al: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64:1404-1410
64. Sabbagh MN, Adler CH, Lahti TJ, et al: Parkinson disease with dementia: Comparing patients with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009; 23:295-297
65. Aarsland D, Kvaloy JT, Andersen K, et al: The effect of age of onset of PD on risk of dementia. J Neurol 2007; 254:38-45
66. Moghbel MC, Saboury B, Basu S, et al: Amyloid-beta imaging with PET in Alzheimer's disease: Is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2012; 39: 202-208
67. Villemagne VL, Klunk WE, Mathis CA, et al: A beta imaging: Feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39:209-219
68. Sved berg MM, Hall H, Hellstrom-Lindahl E, et al: [(11)C]PIBamyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009; 54:347-357
69. Driscoll I, Troncoso JC, Rudow G, et al: Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 124:823-831
70. Herholz K, Ebmeier K: Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011; 10:667-670
71. Fujishiro H, Ferman TJ, Boeve BF, et al: Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp Neurol 2008; 67:649-656
72. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al: Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: A prospective study with pathological verification of diagnosis. Brain 2009; 132:195-203
73. Whitwell JL, Josephs KA, Murray ME, et al: MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study. Neurology 2008; 71:743-749
74. Braak H, Braak E: Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 1991; 82:239-259